Phase 2 N=108 Chronic Low Back Pain Research Project
Chronic Low Back Pain
Primary: Transformed Descriptor Differential Scale-Pain Intensity Scores Adjusted for Time — 0.6683; 0.6988 units on a scale — p=0.4237
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=312 A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
Influenza
Primary: Number of Seroconverted Subjects Against the A/Indonesia/5/2005 (H5N1) Strain of Influenza Disease. — 63; 64; 53; 54 Subjects
Phase 2 N=113 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Phase 2 N=841 Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain. — 71; 81; 73; 65 Subjects
Phase 2 N=370 S. Japonicum and Pregnancy Outcomes
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Phase 2 N=38 Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures
Femoral Neck Fractures · Hip Fractures
Primary: Number of Participants Reporting at Least One NRS Rating — 18; 18 Participants
Phase 2 N=43 Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
Schizophrenia
Primary: Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS) — 17.63; 18.29; 17.06; 17.08 units on a scale
Phase 2 N=462 A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
Hepatitis C
Primary: The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24) — 69.7; 66.2; 60.6; 66.7…
Phase 2 N=216 A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
Schizophrenia
Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 — -13.3; -17.0; -12.7 Units on a scale — p=0.8590
Phase 2 N=116 A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection
Hepatitis C, Chronic
Primary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and…
Phase 2 N=34 Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Yale Brown Obsessive Compulsive Scale — 19.14; 21.24 Scores on a scale — p=<0.05
Phase 2 N=52 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Adult Acute Monoblastic Leukemia (M5a) · Adult Acute Monocytic Leukemia (M5b) · Adult Acute Myeloblastic Leukemia With Maturation (M2)
Primary: Dose Limiting Toxicity — 0; 1; 0; 0 participants
Phase 2 N=53 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities — 0 participants
Phase 2 N=33 Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals
Cocaine Dependence
Primary: Salivary Cortisol Levels — 0.18; 0.22 mg/dl